ArticleWorld journal of surgical oncology2026
Germline HLA-I genotypes predict pathologic response and survival outcomes in esophageal cancer patients undergoing neoadjuvant immunochemotherapy: a retrospective cohort study.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeoadjuvant immunochemotherapy (nICT) has reshaped the treatment paradigm for locally advanced esophageal cancer (EC), but patient responses remain highly heterogeneous. Reliable biomarkers to predict therapeutic benefit are urgently needed. Class I human leukocyte antigen (HLA-I) molecules are essential for anti-tumor immunity, presenting neoantigens to cytotoxic T lymphocytes.This study investigated the relationship between germline HLA-I genotypes and treatment response in patients with esophageal cancer receiving nICT.
methodsWe retrospectively analyzed 30 Chinese EC patients who underwent surgery following nICT. High-resolution sequencing was used to determine germline HLA-I genotypes. Associations between specific HLA alleles and both short-term pathologic response and long-term survival outcomes, including pathologic complete response (pCR) and event-free survival (EFS) were evaluated.
resultsHLA-A*11:01 carriers exhibited significantly prolonged EFS compared with non-carriers (P = 0.015). In contrast, the HLA-A*24:02 allele was more frequent in non-pCR patients (50.0% vs. 12.5%, P = 0.064), and shorter EFS was observed among carriers (median 16.0 vs. 38.8 months, P = 0.063), although these differences did not reach statistical significance. HLA-I homozygosity was more common among patients who achieved pCR (75.0% vs. 27.3%, P = 0.034).
conclusionIn this small retrospective cohort, germline HLA-I genotypes were associated with differences in pathologic response and event-free survival following nICT. These findings should be interpreted as exploratory and hypothesis-generating, requiring validation in larger prospective studies before clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.